# Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant

> **NCT02611063** · PHASE1 · COMPLETED · sponsor: **Stefanie Sarantopoulos, MD, PhD.** · enrollment: 22 (actual)

## Conditions studied

- Hematological Malignancies

## Interventions

- **DRUG:** fostamatinib

## Key facts

- **NCT ID:** NCT02611063
- **Lead sponsor:** Stefanie Sarantopoulos, MD, PhD.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2021-02
- **Final completion:** 2022-02-22
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2023-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02611063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02611063, "Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT02611063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*